Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 28, 2016; 22(4): 1421-1432
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1421
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1421
Table 3 Recommedation for therapy in patients with genotypes 2 and 3
Patient characterization | Recommended | Duration (wk) | Scientific evidence |
Genotype 2 naive noncirrhotic/cirrhotic | SOF + RBV | 12 | Fission positron |
SOF + PEG + RBV | 12 | Lonestar-2 | |
Genotype 2 retretated noncirrhotic | SOF + RBV | 12 | Fussion valence |
SOF + PEG + RBV | 12 | Lonestar-2 | |
Genotype 2 retreated cirrhotic | SOF + PEG + RBV | 12 | Lonestar-2 |
SOF + RBV | 16 | Fussion valence | |
Genotype 3 naive and retreated noncirrhotic/cirrhotic | SOF + RBV | 24 | Valence |
SOF + PEG + RBV | 12 | Lonestar-2 | |
SOF + LDV + RBV | 12 | Electron-2 | |
SOF + DVC (No en cirróticos) | 12 | Ally-3 |
- Citation: González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol 2016; 22(4): 1421-1432
- URL: https://www.wjgnet.com/1007-9327/full/v22/i4/1421.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i4.1421